Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Immuno-oncology Biomarkers in Clinical Trials

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 11 of 11
Introduction
Thomas Frank Gajewski
Univ. of Chicago, Chicago, IL, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
First-in-human PET imaging with the PD-L1 antibody 89Zr-atezolizumab
Frederike Bensch
University Medical Center Groningen, Groningen, Netherlands
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Discussant
David A. Mankoff
University of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial
Roberta Zappasodi
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Discussant
Drew M. Pardoll
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Frederick L Locke
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with axicabtagene ciloleucel (KTE-C19)
Frederick L. Locke
H. Lee Moffitt Cancer Center, Tampa, FL, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Discussant
Renier J. Brentjens
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141
Robert L. Ferris
University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141
Robert L. Ferris
University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Discussant
Mario Sznol
Yale Cancer Ctr., New Haven, CT, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 11 of 11